The only way to reduce asymmetry is to provide transparency and empower enrollees to decide among plans in view of not just their medical benefits (with advice from providers), but also their costs.

Proliferation of non-traditional competitors and stakeholders, including non-traditional flow of innovation, and a general perception of inflated cost of healthcare, challenge the legacy model of drug development and commercialization.